Meta‐analyses of adjuvant therapy trials have provided estimates for breast cancer subtypes, including oestrogen receptor (ER)‐positive tumours at twenty years3 and HER2‐positive tumours at ten years.7 This evidence concerns the gene ERBB2 and breast cancer.